These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 11835924)

  • 1. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.
    White WB; Faich G; Whelton A; Maurath C; Ridge NJ; Verburg KM; Geis GS; Lefkowith JB
    Am J Cardiol; 2002 Feb; 89(4):425-30. PubMed ID: 11835924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.
    White WB; Faich G; Borer JS; Makuch RW
    Am J Cardiol; 2003 Aug; 92(4):411-8. PubMed ID: 12914871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.
    Whelton A; Lefkowith JL; West CR; Verburg KM
    Kidney Int; 2006 Oct; 70(8):1495-502. PubMed ID: 16941030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of celecoxib in treating symptoms of viral pharyngitis: a double-blind, randomized study of celecoxib versus diclofenac.
    Weckx LL; Ruiz JE; Duperly J; Mendizabal GA; Rausis MB; Piltcher SL; Saffer M; Matsuyama C; Levy S; Fort JG
    J Int Med Res; 2002; 30(2):185-94. PubMed ID: 12025527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
    Chan FK; Hung LC; Suen BY; Wu JC; Lee KC; Leung VK; Hui AJ; To KF; Leung WK; Wong VW; Chung SC; Sung JJ
    N Engl J Med; 2002 Dec; 347(26):2104-10. PubMed ID: 12501222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
    Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
    Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE;
    Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.
    Emery P; Zeidler H; Kvien TK; Guslandi M; Naudin R; Stead H; Verburg KM; Isakson PC; Hubbard RC; Geis GS
    Lancet; 1999 Dec 18-25; 354(9196):2106-11. PubMed ID: 10609815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?
    Simon LS
    Gastroenterol Clin North Am; 2001 Dec; 30(4):1011-25, viii. PubMed ID: 11764530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic model of long-term use of celecoxib in patients with osteoarthritis.
    Loyd M; Rublee D; Jacobs P
    BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip.
    Hawel R; Klein G; Singer F; Mayrhofer F; Kähler ST
    Int J Clin Pharmacol Ther; 2003 Apr; 41(4):153-64. PubMed ID: 12708604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
    Kellner HL; Li C; Essex MN
    Curr Med Res Opin; 2012 Sep; 28(9):1537-45. PubMed ID: 22852870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib clinical profile.
    Tive L
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():21-8; discussion 57-9. PubMed ID: 11276798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.